Severe hypophosphataemia after intravenous iron administration

BMJ Case Reports

Volumn 2017, Issue , 2017, Pages

  Anand, Gurpreet ^a   Schmid, Christoph ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CYANOCOBALAMIN; FERRIC CARBOXYMALTOSE; LEVONORGESTREL; IRON;

ADRENAL FUNCTION; ADULT; ALCOHOL CONSUMPTION; ARTICLE; AWARENESS; CASE REPORT; DISEASE EXACERBATION; DISEASE SEVERITY; ERYTHROPOIESIS; FATIGUE; FEMALE; FOLLOW UP; GENETIC TRANSCRIPTION; GLOMERULUS FILTRATION RATE; HUMAN; HYPOPHOSPHATEMIA; IRON DEFICIENCY ANEMIA; KIDNEY TUBULE; LUNG AUSCULTATION; MENSTRUATION; MYALGIA; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PHYSICIAN; SMOKING; ANEMIA, IRON-DEFICIENCY; CHEMICALLY INDUCED; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; VITAMIN D DEFICIENCY;

ADMINISTRATION, INTRAVENOUS; ADULT; ANEMIA, IRON-DEFICIENCY; FEMALE; HUMANS; HYPOPHOSPHATEMIA; IRON; VITAMIN D DEFICIENCY;

EID: 85015322728     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2016-219160     Document Type: Article

References (16)

1. Hempel EV, Bollard ER. The evidence-based evaluation of iron deficiency anemia. Med Clin North Am 2016;100:1065-75.
2. Okada M, Imamura K, Fuchigami T, et al. 2 cases of nonspecific multiple ulcers of the small intestine associated with osteomalacia caused by long-term intravenous administration of saccharated ferric oxide. Nippon Naika Gakkai Zasshi 1982;71:1566-72.
3. Schouten B, Hunt P, Livesey J, et al. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose. JCEM 2009;94:2332-7.
4. Shimizu Y, Tada Y, Yamauchi M, et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone 2009;45:814-16.
5. Van Wyck DB, Mangione A, Morrison J, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding. Transfusion 2009;49:2719-28.
6. Yamamoto S, Okada Y, Mori H, et al. Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide. Intern Med 2012;51:2375-8.
7. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 2013;28:1793-803.
8. Hu MC, Shiizaki K, Kuro-o M, et al. Fibroblast growth factor 23 and klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 2013;75:503-33.
9. Blazevic A, Hunze J, Boots JM. Severe hypophosphaetemia after intravenous iron administration. Neth J Med 2014;72:49-53.
10. Vandemergel X, Vandergheynst F. Potentially life-threatening phosphate diabetes induced by ferric carboxymaltose injection. Case Rep Endocrinol 2014; 2014:843689.
11. Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol 2015;2015:468675.
12. Glendenning P, Bell DA, Clifton-Bligh RJ. Investigating hypophosphataemia. BMJ 2014;348:g3172.
13. Schaefer B, Würtinger P, Finkenstedt A, et al. Choice of high-dose intravenous iron preparation determines hypophosphatemia risk. PLoS ONE 2016;11: e0167146.
14. Brodehl J, Krause A, Hoyer PF. Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvoet. Pediatr Nephrol 1988;2:183-9.
15. Bauer C, Brücker R, Bützberger S, et al. Hypophosphataemia-inducing mesenchymal tumour in the foot. BMJ Case Rep 2010;2010:pii:bcr0620092034
16. Bager P, Hvas CL, Dahlerup JF. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Br J Clin Pharmacol 2016.